OVERVIEW
Drug Overview
Product Profiles
Revlimid : NHL: Follicular lymphoma (FL)
Revlimid : NHL: Diffuse large B-cell lymphoma (DLBCL)
Revlimid : Multiple myeloma
Revlimid : NHL: Mantle cell lymphoma (MCL)
LIST OF FIGURES
Figure 1: Revlimid for follicular lymphoma – SWOT analysis
Figure 2: The authors drug assessment summary of Revlimid for follicular lymphoma
Figure 3: The authors drug assessment summary of Revlimid for follicular lymphoma
Figure 4: Revlimid sales for follicular lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 5: Revlimid for diffuse large B-cell lymphoma – SWOT analysis
Figure 6: The authors drug assessment summary for Revlimid in diffuse large B-cell lymphoma
Figure 7: The authors drug assessment summary for Revlimid in diffuse large B-cell lymphoma
Figure 8: Revlimid sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 9: Revlimid for multiple myeloma – SWOT analysis
Figure 10: The authors drug assessment summary of Revlimid for multiple myeloma
Figure 11: The authors drug assessment summary of Revlimid for multiple myeloma
Figure 12: Revlimid sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
Figure 13: Revlimid for mantle cell lymphoma – SWOT analysis
Figure 14: The authors drug assessment summary of Revlimid in mantle cell lymphoma
Figure 15: The authors drug assessment summary of Revlimid in mantle cell lymphoma
LIST OF TABLES
Table 1: Revlimid drug profile
Table 2: Revlimid pivotal trial data in follicular lymphoma
Table 3: Revlimid sales for follicular lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 4: Revlimid drug profile
Table 5: Revlimid ongoing pivotal trial in diffuse large B-cell lymphoma
Table 6: Early-phase data for Revlimid in diffuse large B-cell lymphoma
Table 7: Revlimid sales for diffuse large B-cell lymphoma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 8: Revlimid drug profile
Table 9: Revlimid pivotal trial data in multiple myeloma
Table 10: Revlimid ongoing clinical trials in multiple myeloma
Table 11: Revlimid sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
Table 12: Patients treated with Revlimid across the US, Japan, and five major EU markets, by country, 2017–26
Table 13: Revlimid drug profile
Table 14: Revlimid pivotal trial data in mantle cell lymphoma
Table 15: Revlimid other trial data in mantle cell lymphoma
Table 16: Revlimid ongoing clinical trials in mantle cell lymphoma
